XBIT - XBiotech Inc.

2.54
-0.035   -1.378%

Share volume: 22,913
Last Updated: 04-28-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.12%

PREVIOUS CLOSE
CHG
CHG%
$2.58
-0.04
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
5%
Profitability 0%
Dept financing 1%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
1.20%
1 Month
11.89%
3 Months
0   0%
6 Months
7.17%
1 Year
-11.50%
2 Year
-67.27%
Key data
Stock price
$2.54
P/E Ratio 
N/A
DAY RANGE
$2.54 - $2.65
EPS 
-$1.49
52 WEEK RANGE
$2.09 - $3.61
52 WEEK CHANGE
-$16.45
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
30.488 M
DIVIDEND
$2.0995
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-09-2025
BETA 
0.92
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$24,487
AVERAGE 30 VOLUME 
$25,394
Company detail
CEO: John Simard
Region: US
Website: xbiotech.com
Employees: 100
IPO year: 2015
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

XBiotech Inc. discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis.

Recent news